Hereditary Spastic Paraplegia Type 50 (SPG50) research hub

A Phase IIb, Monocentric, Non-Profit, Open-label Trial for the Intrathecal Administration of AAV9/AP4M1 for Hereditary Spastic Paraplegia Type 50 (SPG50)

This study is looking into a new treatment called Melpida for a rare genetic condition called SPG50, which affects movement. It aims to see if Melpida can help improve how people with SPG50 move by tracking their walking and other physical abilities over time.